GLUE - monterosatx.com Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand Monte Rosa Therapeutics (GLUE)

The battle for unique patents in targeted oncology is creating severe pressure on Monte Rosa Therapeutics (GLUE). The balance between the P/E multiple and growth reflects the market reaction to these risks, while the 0.00 indicator confirms the current level. Development relies on the QuEEN AI platform, and the high cost of trials combined with FDA oversight create insurmountable barriers for new entrants.

GLUE: monterosatx.com Price/Earnings to Growth Multiple 07/04/2022 - 11/10/2026

Metric breakdowns and analytics for Monte Rosa Therapeutics (GLUE)

- market value and analyst target forecast:
Price Rate Chart Monte Rosa Therapeutics Inc|GLUE - Consensus Target
- market capitalization statistics:
Market Value Monte Rosa Tx|GLUE - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Accounting Value of a Share Monte Rosa Therapeutics|GLUE - Company Net Assets|Market Cap to Book Value Multiple monterosatx.com|GLUE - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Monte Rosa Therapeutics|GLUE - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital monterosatx.com|GLUE - Company Aggregate Debts|Debt to Net Assets Monte Rosa Tx|GLUE - Company Long-Term Debts|Short-Term Debt Monte Rosa Therapeutics|Intermediate Liquidity Ratio monterosatx.com
- earnings and valuation multiples information:
GLUE - Net Profit|Expected Net Profit Monte Rosa Therapeutics|GLUE - P/E Multiple|Price to Future Earnings Ratio Monte Rosa Corp|GLUE - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Monte Rosa Tx|GLUE - Operating profit before deduction of amortization|Earnings per share for the last four quarters Monte Rosa Therapeutics|GLUE - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months monterosatx.com|GLUE - Earnings growth in current year|Expected net earnings per share growth next year Monte Rosa Therapeutics
General company analysis:Monte Rosa Therapeutics
Signature product of monterosatx.com

Monte Rosa Therapeutics (GLUE) leverages its monopoly position in the targeted protein degradation segment to establish premium pricing for its oncology drugs. The PEG ratio allows for an assessment of the fairness of market value relative to business expansion, where values below one signal an undervaluation of potential, as clearly confirmed by the historical PEG level.

Competing companies

Genmab AS (GMAB) - Price to Net Income Growth Ratio|Exelixis Corp - Price/Earnings to Growth Multiple|Nuvalent Therapeutics (NUVL) - Price to Earnings Adjusted for Growth Rate|KYMR: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio IDYA (ideayabio.com)|ELVN (Enliven Therapeutics, Inc.) - Price/Earnings to Growth Multiple|ORIC: Company Value to Earnings Growth Ratio|RLAY (Relay Pharma) - PEG Multiple|PEG Multiple Nurix Corp|Price/Earnings to Growth Ratio Tyra Biosciences, Inc. (TYRA)|VSTM (verastem.com) - Growth-Adjusted Payback Ratio|PEG Multiple CGEM (Cullinan Therapeutics, Inc.)|Price to Net Income Growth Ratio Immuneering Corp|C4 Tx - PEG Multiple|Price to Earnings Adjusted for Growth Rate Black Diamond Therapeutics, Inc|RPTX (Repare Therapeutics) - Price/Earnings to Growth Multiple|PMVP: Company Value to Earnings Growth Ratio|KPTI (Karyopharm Therapeutics, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Propanc Biopharma, Inc. PPCB|PEG Multiple BGMS|aadibio.com - Growth-Adjusted P/E Ratio|Aileron Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio BPMC|GLYC: Price/Earnings to Growth Multiple|SpringWorks Therapeutics Inc. - Company Value to Earnings Growth Ratio